Drugs / Lifirafenib
Lifirafenib
also known as
BGB-283 · Beigene-283 · BGB-283 sesqui-maleate · LIFIRAFENIB MALEATE · Lifirafenib sesquimaleate
Small molecule targets BRAF, EGFR via inhibition
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03905148 | May 2019 → Oct 2024 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT03641586 | Oct 2015 → Dec 2016 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT02610361 | Nov 2013 → Oct 2017 | cancer | BeiGene | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lifirafenib | “Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.” PMID 32182156 ↗ Mar 2020 |
| Known as | Beigene-283 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4209157 ↗ |
| Known as | BGB-283 | “Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.” PMID 32182156 ↗ Mar 2020 |
| Known as | BGB-283 sesqui-maleate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4209157 ↗ |
| Known as | LIFIRAFENIB MALEATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4209157 ↗ |
| Known as | Lifirafenib sesquimaleate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4209157 ↗ |
| Action | Inhibit | “Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR.” PMID 32182156 ↗ Mar 20201“Serine/threonine-protein kinase B-raf inhibitor” CHEMBL4209157 ↗ |
| Modality | Small molecule | — CHEMBL4209157 ↗ |
| Target | BRAF | “Serine/threonine-protein kinase B-raf inhibitor” CHEMBL4209157 ↗ |
| Target | EGFR | “Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR.” PMID 32182156 ↗ Mar 2020 |